A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients
Clinical Trial Grant
Administered By
Institutes and Centers
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
July 1, 2014
End Date
June 30, 2017
Administered By
Institutes and Centers
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
July 1, 2014
End Date
June 30, 2017